Estrella Immunopharma Statistics
Estrella Immunopharma (ESLA) Stock Statistics & Valuation Metrics
Total Valuation
Estrella Immunopharma has a market cap or net worth of $22.36M. The enterprise value is $41.54T.
- Market Cap
- $22.36M
- Enterprise Value
- $41.54T
Share Statistics
Estrella Immunopharma has 43,497,864 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 43,497,864
- Owned by Insiders
- 1.75%
- Owned by Institutions
- 2.43%
Financial Efficiency
Estrella Immunopharma’s return on equity (ROE) is 1.26 and return on invested capital (ROIC) is 126.01%.
- Return on Equity (ROE)
- 1.26
- Return on Assets (ROA)
- -4.11
- Return on Invested Capital (ROIC)
- 126.01%
- Return on Capital Employed (ROCE)
- 1.26
- Revenue Per Employee
- 0
- Profits Per Employee
- -4.35M
- Employee Count
- 3
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Estrella Immunopharma is -2.09. Estrella Immunopharma’s PEG ratio is -0.11.
- PE Ratio
- -2.09
- PS Ratio
- 0.00
- PB Ratio
- -2.97
- Price to FCF
- -2.38
- Price to Operating Cash Flow
- -2.36
- PEG Ratio
- -0.11
Income Statement
In the last 12 months, Estrella Immunopharma had revenue of 0 and earned -13.06M in profits. Earnings per share was -0.35.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -13.06M
- Pretax Income
- -13.06M
- Net Income
- -13.06M
- EBITDA
- -13.06M
- Earnings Per Share (EPS)
- -0.35
Cash Flow
In the last 12 months, operating cash flow was -9.38M and capital expenditures 0, giving a free cash flow of -9.38M billion.
- Operating Cash Flow
- -9.38M
- Free Cash Flow
- -9.38M
- Free Cash Flow per Share
- -0.22
Dividends & Yields
Estrella Immunopharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -41.97%
- Earnings Yield
- -45.30%
Stock Price Statistics
- Beta
- 1.93
- 52-Week Price Change
- -76.64%
- 50-Day Moving Average
- 0.55
- 200-Day Moving Average
- 0.96
- Relative Strength Index (RSI)
- 47.40
- Average Volume (3m)
- 2.00M
Financial Position
Estrella Immunopharma as a current ratio of 0.12, with Debt / Equity ratio of 0.00%
- Current Ratio
- 0.12
- Quick Ratio
- 0.12
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.11
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Estrella Immunopharma has paid 838 in taxes.
- Income Tax
- 838
- Effective Tax Rate
- -0.00
Enterprise Valuation
Estrella Immunopharma EV to EBITDA ratio is -2.27, with an EV/FCF ratio of -2.37.
- EV to Sales
- 0.00
- EV to EBITDA
- -2.27
- EV to Free Cash Flow
- -2.37
- EV to Operating Cash Flow
- -2.37
Balance Sheet
Estrella Immunopharma has $146.67K in cash and marketable securities with $0.00 in debt, giving a net cash position of $146.67K billion.
- Cash & Marketable Securities
- $146.67K
- Total Debt
- $0.00
- Net Cash
- $146.67K
- Net Cash Per Share
- $0.00
- Tangible Book Value Per Share
- -$0.17
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Estrella Immunopharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 24.03%

